{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:50:58Z","timestamp":1795020658377,"version":"4.10.1"},"reference-count":39,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2017,11,23]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Placebo-controlled trials have shown that caffeine is highly effective in treating apnoea of prematurity and reduces the risk of bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment (NDI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To identify, appraise and summarise studies investigating the modulating effect of different caffeine dosages.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review identified all randomised controlled trials (RCTs) comparing a high versus a standard caffeine treatment regimen in infants with a gestational age &lt;32 weeks, by searching the main electronic databases and abstracts of the Pediatric Academic Societies. Studies comparing caffeine to placebo or theophylline only were excluded. Primary outcomes were BPD and mortality at 36 weeks postmenstrual age. Secondary key-outcome was neurodevelopmental outcome at 12 and 24 months corrected age. Meta-analysis was performed using RevMan 5.3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six RCTs including 620 infants were identified. Meta-analysis showed a significant decrease in BPD, the combined outcome BPD or mortality, and failure to extubate in infants allocated to a higher caffeine dose. No differences were found in mortality alone and NDI. The quality of the outcome measures were deemed low to very low according to the Grading of Recommendations Assessment, Development and Evaluation guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although this review suggests that administering a higher dose of caffeine might enhance its beneficial effect on death or BPD, firm recommendations on the optimal caffeine dose cannot be given due to the low level of evidence. A large RCT is urgently needed to confirm or refute these findings and determine the optimal dose of caffeine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/archdischild-2017-313556","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T12:20:24Z","timestamp":1518006024000},"page":"F523-F529","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["High versus standard dose caffeine for apnoea: a systematic review"],"prefix":"10.1136","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-2735","authenticated-orcid":false,"given":"Roos","family":"Vliegenthart","sequence":"first","affiliation":[{"name":"Department of Neonatology, Emma Children\u2019s Hospital, Academic Medical Center, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Miedema","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emma Children\u2019s Hospital, Academic Medical Center, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J","family":"Hutten","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emma Children\u2019s Hospital, Academic Medical Center, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton H","family":"van Kaam","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emma Children\u2019s Hospital, Academic Medical Center, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wes","family":"Onland","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emma Children\u2019s Hospital, Academic Medical Center, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2025090511252584000_103.6.F523.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80349-X"},{"key":"2025090511252584000_103.6.F523.2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.1_Spec_No.70"},{"key":"2025090511252584000_103.6.F523.3","doi-asserted-by":"publisher","DOI":"10.1159\/000329922"},{"key":"2025090511252584000_103.6.F523.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2013.05.026"},{"key":"2025090511252584000_103.6.F523.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-005-1623-1"},{"key":"2025090511252584000_103.6.F523.6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0095-5108(18)31165-5","article-title":"Methylxanthines in apnea of prematurity","volume":"6","author":"Aranda","year":"1979","journal-title":"Clin Perinatol"},{"key":"2025090511252584000_103.6.F523.7","doi-asserted-by":"crossref","unstructured":"Henderson-Smart DJ , De Paoli AG . Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 2010:CD000140.doi:10.1002\/14651858.CD000140.pub2","DOI":"10.1002\/14651858.CD000140.pub2"},{"key":"2025090511252584000_103.6.F523.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.04.040"},{"key":"2025090511252584000_103.6.F523.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.09.069"},{"key":"2025090511252584000_103.6.F523.10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa054065","article-title":"Caffeine therapy for apnea of prematurity","volume":"354","author":"Schmidt","year":"2006","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090511252584000_103.6.F523.11","doi-asserted-by":"crossref","unstructured":"Henderson-Smart DJ , Davis PG . Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010:CD000139.doi:10.1002\/14651858.CD000139.pub2","DOI":"10.1002\/14651858.CD000139.pub2"},{"key":"2025090511252584000_103.6.F523.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073679"},{"key":"2025090511252584000_103.6.F523.13","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181898b6f"},{"key":"2025090511252584000_103.6.F523.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90097-7"},{"key":"2025090511252584000_103.6.F523.15","unstructured":"Higgins JPT GS . Cochrane handbook for systematic reviews of interventions version 5.1.0. London, UK: The Cochrane Collaboration, 2011."},{"key":"2025090511252584000_103.6.F523.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025090511252584000_103.6.F523.17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000448941","article-title":"Doxapram treatment for apnea of prematurity: a systematic review","volume":"111","author":"Vliegenthart","year":"2017","journal-title":"Neonatology"},{"key":"2025090511252584000_103.6.F523.18","unstructured":"GDT G. Gradepro. Canada: McMaster Univerity. www.gradepro.org 2016."},{"key":"2025090511252584000_103.6.F523.19","unstructured":"Centre NC. Review manager. Version 5.3. Copenhagen: Cochrane Collaboration. 2012."},{"key":"2025090511252584000_103.6.F523.20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00007691-199202000-00003","article-title":"Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants","volume":"14","author":"Romagnoli","year":"1992","journal-title":"Ther Drug Monit"},{"key":"2025090511252584000_103.6.F523.21","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.4_Spec_No.425"},{"key":"2025090511252584000_103.6.F523.22","unstructured":"Group CNR. \u00a0Resources for review authors. 2017."},{"key":"2025090511252584000_103.6.F523.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2010.01943.x"},{"key":"2025090511252584000_103.6.F523.24","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2002.023432"},{"key":"2025090511252584000_103.6.F523.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2003.00207.x"},{"key":"2025090511252584000_103.6.F523.26","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2015.72"},{"key":"2025090511252584000_103.6.F523.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-015-2494-8"},{"key":"2025090511252584000_103.6.F523.28","unstructured":"Griffiths R . \u00a0The griffiths mental developmental scales. Henley on Thames, UK: Association for Research in Infant and Child Development, 1996."},{"key":"2025090511252584000_103.6.F523.29","doi-asserted-by":"crossref","unstructured":"Bayley N . Bayley scales of infant and toddler development. 3rd edn. Oxford, UK: Pearson Assesment, 2005.","DOI":"10.1037\/t14978-000"},{"key":"2025090511252584000_103.6.F523.30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clp.2016.07.011","article-title":"The role of caffeine in noninvasive respiratory support","volume":"43","author":"Dobson","year":"2016","journal-title":"Clin Perinatol"},{"key":"2025090511252584000_103.6.F523.31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jpc.13366","article-title":"Use of caffeine for preterm infants in Australia and New Zealand: a survey","volume":"52","author":"Gray","year":"2016","journal-title":"J Paediatr Child Health"},{"key":"2025090511252584000_103.6.F523.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.2024"},{"key":"2025090511252584000_103.6.F523.33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apa.13691","article-title":"Association of early versus late caffeine administration on neonatal outcomes in very preterm neonates","volume":"106","author":"Adzikah","year":"2017","journal-title":"Acta Paediatr"},{"key":"2025090511252584000_103.6.F523.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.01.054"},{"key":"2025090511252584000_103.6.F523.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra067279"},{"key":"2025090511252584000_103.6.F523.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.01.047"},{"key":"2025090511252584000_103.6.F523.37","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.11.1082"},{"key":"2025090511252584000_103.6.F523.38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1041"},{"key":"2025090511252584000_103.6.F523.39","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-013-0487-6"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2017-313556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:49:02Z","timestamp":1757098142000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2017-313556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,10,18]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/archdischild-2017-313556"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2017-313556","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/archdischild-2017-313556.supp1","asserted-by":"subject"}]},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}